Comments on: ESMO September 2017: Results in study Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced or Metastatic RCC

Comments on: ESMO September 2017: Results in study Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced or Metastatic RCC https://www.euog.org/519/esmo-september-2017-results-in-study-nivolumab-plus-ipilimumab-versus-sunitinib-in-first-line-treatment-for-advanced-or-metastatic-rcc/ European Uro-Oncology Group (EUOG) Tue, 26 Sep 2017 14:27:02 +0000 hourly 1 https://wordpress.org/?v=6.9.1